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Abstract
Hepatitis C virus (HCV) is among the most relevant causes of liver cirrhosis and hepatocellular carcinoma. Research is
complicated by a lack of accessible small animal models. The systematic investigation of viruses of small mammals could
guide efforts to establish such models, while providing insight into viral evolutionary biology. We have assembled the so-far
largest collection of small-mammal samples from around the world, qualified to be screened for bloodborne viruses,
including sera and organs from 4,770 rodents (41 species); and sera from 2,939 bats (51 species). Three highly divergent
rodent hepacivirus clades were detected in 27 (1.8%) of 1,465 European bank voles (Myodes glareolus) and 10 (1.9%) of 518
South African four-striped mice (Rhabdomys pumilio). Bats showed anti-HCV immunoblot reactivities but no virus detection,
although the genetic relatedness suggested by the serologic results should have enabled RNA detection using the broadly
reactive PCR assays developed for this study. 210 horses and 858 cats and dogs were tested, yielding further horse-
associated hepaciviruses but none in dogs or cats. The rodent viruses were equidistant to HCV, exceeding by far the
diversity of HCV and the canine/equine hepaciviruses taken together. Five full genomes were sequenced, representing all
viral lineages. Salient genome features and distance criteria supported classification of all viruses as hepaciviruses.
Quantitative RT-PCR, RNA in-situ hybridisation, and histopathology suggested hepatic tropism with liver inflammation
resembling hepatitis C. Recombinant serology for two distinct hepacivirus lineages in 97 bank voles identified
seroprevalence rates of 8.3 and 12.4%, respectively. Antibodies in bank vole sera neither cross-reacted with HCV, nor the
heterologous bank vole hepacivirus. Co-occurrence of RNA and antibodies was found in 3 of 57 PCR-positive bank vole sera
(5.3%). Our data enable new hypotheses regarding HCV evolution and encourage efforts to develop rodent surrogate
models for HCV.
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Introduction
Hepatitis C virus is one of the leading causes of human
morbidity and mortality due to hepatitis, liver cirrhosis, and
hepatocellular carcinoma [1,2,3]. It has become the main reason
for liver transplantation in developed countries and represents an
economic burden exceeding 1 billion US$ of direct health costs
[4,5]. New estimates of the burden of disease suggest at least 185
million individuals worldwide to have been seropositive in 2005,
with a tendency to increase [6]. Treatment has considerably
improved due to the optimization of antiviral regimens and the
advent of new antiviral drugs [7,8,9]. However, treatment in
resource-limited settings is hardly accessible [10]. The most
effective instrument to prevent new infections with HCV would
be a prophylactic vaccine. Unfortunately, chimpanzees are the
only known animal species to adequately reflect human HCV
infection [11]. Vaccine development is hampered by the lack of a
small animal model accessible at early stages of vaccine
development [12,13]. Mice cannot be infected with HCV [14],
but rats and mice engrafted with human hepatoma cells or
transgenic for human CD81 and other co-receptor molecules have
been proposed [12,15,16,17]. Mouse-adapted HCV has also been
generated [16,18]. Still, these models are highly demanding from a
technical point of view and reflect only parts of the pathogenesis
and lifecycle of HCV, precluding their wide application [12,19].
A HCV-related hepacivirus of unknown origin, termed GBV-B,
has been used as a surrogate model for HCV infection involving
New World monkeys, where it causes hepatitis upon experimental
inoculation [20,21]. The use of a surrogate model based on a
related virus indicates a way to study HCV pathogenesis and
immunity, even though neither monkeys nor apes are acceptable
laboratory models in terms of accessibility and ethics [12,13,22].
Non-Primate hepaciviruses related to HCV have also been
detected in dogs and horses [23,24]. While horses cannot be
considered as laboratory models, dogs at least have compatible
body sizes. However, additional to ethical controversies, infected
dogs showed grossly deviating pathology in that they appeared to
have higher virus concentrations in respiratory specimens than in
the liver [23]. So far there is no evidence of antibodies against the
virus in dogs, limiting their utility as a vaccination challenge model
[23,24]. No hepaciviruses have been detected in other animals that
could be kept in laboratories with reasonable effort, and under
ethically acceptable conditions.
The targeted identification of animal hepaciviruses might help
elucidating the obscure origins of HCV and yield more accessible
HCV surrogate models. We have recently demonstrated that the
systematic investigation of small mammal reservoirs can yield
novel viruses that are genetically closely related to human
pathogenic viruses, such as the paramyxoviruses mumps and
Nipah virus [25]. Biological and ecological considerations direct
research interests to animals with properties supportive of virus
maintenance. The close social interaction of certain bat species
forming large and dense social groups favors virus maintenance
[25,26]. Virus spreading by bats may be facilitated by their
migratory lifestyle, but also by human activities such as hunting of
bats as bushmeat and human invasion of remote habitats
[27,28,29]. Several rodent species are also in focus as potential
virus reservoirs, as they constitute habitat generalists and follow
human civilization, providing opportunities for virus transmission
[30,31]. Even though rodents form smaller social groups than bats,
some rodent species have a high population turnover, which
should enable efficient maintenance of viruses through the
continuous replenishment of susceptible individuals [26,32].
Among terrestrial mammals, rodents and bats together constitute
about two thirds of the 5,487 known mammalian species [33].
Screening of wild mammals with a view on laboratory models
should be oriented by criteria such as small body size and the
ability to adapt to laboratory conditions, which applies to rodents,
but not bats [12,34]. Here we have investigated 7,709 bats and
rodents pertaining to 92 species sampled globally in ten tropical
and temperate countries. The investigation was complemented by
a comparison of virus diversity in 1,068 horses, cats and dogs.
Materials and Methods
Ethics statement
All animals were handled according to national and European
legislation, namely the EU council directive 86/609/EEC for the
protection of animals. For all individual sampling sites, study
protocols including trapping, sampling and testing of animals were
approved by the responsible animal ethics committees as detailed
below. All efforts were made leave animals unharmed or to
minimize suffering of animals. Any surgical procedure was
performed under sodium pentobarbital/ketamine anesthesia.
Trapping of rodents in Germany was conducted in the framework
of hantavirus monitoring activities and was coordinated by the
Friedrich-Loeffler-Institut, the Federal Research Institute for
Animal Health. Rodent monitoring in the federal states Mecklen-
burg-Western Pomerania, Thuringia, Baden-Wuerttemberg and
North Rhine Westphalia was coordinated by the Julius Ku¨hn
Institute (permit numbers LALLF M-V/TSD/7221.3-2.1-030/09,
TH 15-107/09, BW 35-9185.82/0261 and NW 20.09.210.
Additional animals were provided by forest institutions and pest
management institutions in Mecklenburg-Western Pomerania,
Thuringia, Brandenburg, Lower Saxony, Baden-Wuerttemberg,
Berlin and Budapest which caught and sacrificed the animals during
their official duties without necessity of further permits. Rodents and
other small mammals trapped by cats were included in the
investigations. Rodent sampling in South Africa was licensed by
Cape Nature under permit numbers 317/2003 and 360/2003.
Rodent sampling in The Netherlands was licensed by the Dutch
animal ethic committee (DEC) under permit numbers 200700119,
200800113 and 200800053. Rodent sampling in Thailand was
granted by the Agricultural Zoology Research Group, Department
of Agriculture, Thailand (permit no. KU./14-182). Rodent
Author Summary
The hepatitis C virus (HCV) is one of the most relevant
causes of liver disease and cancer in humans. The lack of a
small animal models represents an important hurdle on our
way to understanding, treating, and preventing hepatitis C.
The investigation of small mammals could identify virus
infections similar to hepatitis C in animals that can be kept
in laboratories, such as rodents, and can also yield insights
into the evolution of those ancestral virus lineages out of
which HCV developed. Here, we investigated a worldwide
sample of 4,770 rodents, 2,939 bats, 210 horses and 858
cats and dogs for HCV-related viruses. New viruses were
discovered in European bank voles (Myodes glareolus) and
South African four-striped mice (Rhabdomys pumilio). The
disease in bank voles was studied in more detail,
suggesting that infection of the liver occurs with similar
symptoms to those caused by HCV in humans. These
rodents might thus enable the development of new
laboratory models of hepatitis C. Moreover, the phyloge-
netic history of those viruses provides fascinating new ideas
regarding the evolution of HCV ancestors.
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sampling in Gabon was licensed by the Ministry of Water and
Forest, statement 003/MEF/SG/DGEF/DFC from 2011. Rodent
sampling in Mexico was licensed by Secretarı´a del Medio Ambiente
del gobierno de Me´xico (SEMARNAT) under permit number
SGPA/DGVS/08283/12. Horse, dog and cat samples were
collected from regular diagnostic specimens sent to the OIE
Reference Laboratory for Equine Influenza and Herpesviruses at
the Freie Universitaet Berlin. Sampling and capture of bats as well
as sample transfers were done under wildlife permits and ethics
clearances: Panama (Research-Permit STRI: STRI2563 (PI VC)
- IACUC 100316-1001-18/Research-Permit ANAM: SE/A-68-
11/Ethics-Permit: IACUC 100316-1001-18/Export Permits:
SEX/A-30-11, SEX/A-55-11, SEX/A-81-10, SEX-A-26-10);
Ghana (Research Permit: 2008–2010 (A04957)/Ethics-Permit:
CHRPE49/09/Export-Permit: State Agreement between Ghana
and Hamburg (BNI)); Australia (Research Permit: S11828 and
S11762/Ethics-Permit: TRIM 01/1118(2), TRIM 06/3569, and
University of Queensland/Animal Ethics Committee SIB600/05/
DEST/Export-Permit: DE201-12); Papua-New Guinea (Ethics-
Permit: PNG/NatMus/2002/Export-Permit: Conducted by Papua
New Guinea National Museum); Gabon (Ethics-Permit: 00021/
MEFEPA/SG/DGEF/DFC); Germany (Ethics-Permit: LANU
314/5327.74.1.6).
Sampling and RNA purification
For all sampling and exportation of specimens, permission was
obtained from the respective authorities (see Acknowledgement for
individual permits). Animals were caught with mist nets, live or
snap traps, identified by trained field biologists on site or prior to
dissection (where applicable), euthanized and dissected in the
respective laboratories. Canine, feline and equine samples were
routine diagnostic specimens. Between 10–140 mL of blood were
extracted using the Qiagen Viral RNA Mini kit (Qiagen, Hilden,
Germany). Approximately 30 mg of solid organ tissue were
homogenized in a TissueLyser (Qiagen) and purified using the
RNeasy Kit (Qiagen).
Hepacivirus detection and quantification
Six nested PCR assays for amplification of hepacivirus RNA
and two assays targeting the Flaviviridae sister-genera Flavivirus and
Pestivirus were used to ensure broad detection. Highly sensitive
HCV-specific assays targeting the X-tail, NS5B and 59-untrans-
lated genomic regions were used in addition (see Supplementary
Table S2 for oligonucleotide sequences and reaction conditions).
RNA quantification relied on strain-specific real-time RT-PCR
assays and photometrically quantified in vitro RNA transcripts
generated as described previously [35].
Full genome sequencing
No isolation attempts were made due to the small available
specimen quantities and notorious difficulty of hepacivirus
isolation. Instead, those rodent specimens with highest RNA
concentrations were selected for full genome sequencing. Genome-
spanning islets were amplified by PCR using degenerate broadly
reactive oligonucleotides (Supplementary Table S2). Bridging
strain-specific oligonucleotide primers (available upon request)
were then designed to perform long range PCR using the Expand
High Fidelity kit (Roche) on cDNA templates generated with the
SuperScriptIII kit (Invitrogen). Some cDNA templates were
enriched using a Phi29-based hexamer-driven amplification using
a modified protocol of the Qiagen Whole Transcriptome
Amplification kit (Qiagen) as described previously [25]. Amplicons
were Sanger sequenced using a primer walking strategy. The 59-
genome ends were determined using the Roche rapid amplifica-
tion of cDNA ends (RACE) kit (Roche) generating contiguous
PCR amplicons encompassing the complete 59-untranslated
region (59-UTR) and the 59-terminus of the core gene. 454 junior
next generation sequencing was used for confirmation of 59-UTR
sequences. For determination of the 39-genome end, viral RNA
was adenylated using a poly-A-polymerase (Clontech, Paris,
France) followed by 39-RACE using the Invitrogen GeneRacer
Kit (Invitrogen).
Phylogeny
Bayesian tree topologies were assessed with MrBayes V3.1 [36]
using the WAG amino acid substitution matrix and BEAST
V1.7.4 [37] using the GTR model for nucleotide sequences and
the FLU model for amino acid sequences. For MrBayes, two
million MCMC iterations were sampled every 100 steps, resulting
in 20,000 trees. For BEAST, 10,000,000 generations run under a
strict clock were sampled every 1,000 steps, resulting in 10,000
trees. Burn-in was generally 25% of tree replicates.. A human
pegivirus (previously termed GBV-C1; GenBank, U36380) was
used as an outgroup. Maximum Likelihood analyses were used to
confirm Bayesian tree topologies using the WAG amino acid
substitution model and 1,000 bootstrap replicates in PhyML [38].
Trees were visualized in FigTree from the BEAST package and
Densitree [39].
Folding
RNA secondary structures in viral 59- and 39-genome ends were
inferred manually basing on covariant base pairing and thermo-
dynamic predictions using mfold [40] in an alignment of rodent,
primate and canine/equine hepaciviruses generated with MAFFT
[41].
Prediction of signal peptidase cleavage and N-/O-
glycosylation sites
Putative cellular signal peptidase (SP) cleavage sites were
predicted based on artificial neural networks (NN) and hidden
Markov models (HMM) using the SignalP 3.0 Server [42]. N- and
O-glycosylation sites were determined using the online tools
NetNGlyc 1.0 Server and NetOGlyc Server [43,44].
Genome comparison
Putative genes were annotated based on predicted signal
peptidase (SP) cleavage sites (where applicable) and sequence
homology to HCV, GBV-B and canine/equine hepaciviruses.
Alignments were generated using MAFFT [41]. Amino acid
percentage identity matrices were calculated using MEGA5 [45]
with the pairwise deletion option.
Statistics
Comparison of mean virus concentrations was done using an
ANOVA analysis with Scheffe´ post-hoc tests in the SPSS V20
software package (IBM, Ehningen, Germany). Cross-tables were
done using EpiInfo7 (www.cdc.gov/epiinfo).
Serology
HCV Western blot. Western blot (WB) analysis was
performed with commercially available HCV strips (recomBlot
HCV IgG 2.0 and recomLine HCV IgG, Microgen, Neuried,
Germany). Bat and rodent sera were diluted 1:100 for screening.
Horseradish peroxidase-labelled goat anti-bat immunoglobulin (Ig)
conjugate (Bethyl, Montgomery, AL, USA) or goat-anti mouse Ig
(Dianova, Hamburg, Germany) were used as secondary antibodies
(dilution, 1:500). For rodent WB, a tertiary horseradish
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peroxidase-labelled donkey-anti goat Ig (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) was used for signal amplification.
Blots were evaluated following the manufacturer’s instructions.
HCV immunofluorescence assay. An indirect immunoflu-
orescence assay (IFA) was done using HCV-infected HuH7-cells
(strain JC1) or replicon JFH1-transfected cells. Cells were fixed
with paraformaldehyde (4%), permeabilized with 0.5% Triton X-
100 in 16PBS for 5 minutes and processed as described previously
[46]. Bat sera were diluted 1:50. Reactions were detected with
goat-anti-bat Ig (Bethyl, 1:1000) and cyanine 2 (Cy2)–labelled
donkey-anti-goat Ig (Dianova, 1:100). For control reactions, a
polyclonal rabbit NS3-Ig raised against the NS3 helicase domain
of JFH1 (1:400) and an Alexa 568-conjugated goat-anti-rabbit Ig
(Invitrogen, 1:1000) were used.
Rodent hepacivirus immunofluorescence assay. VeroFM
cells were transfected in suspension using FuGENE HD (Promega,
Mannheim, Germany) with 0.75 mg plasmid expressing the
complete His-tagged NS3 proteins of the rodent hepaciviruses
RMU10-3382 (rNS3RMU10-3382) and NLR-AP70 (rNS3AP70)
and fixed 24 hours later with acetone/methanol (80%/20%).
Myodes glareolus sera were tested at screening dilutions of 1:10 and
1:40. For secondary detection, a goat-anti-mouse Ig (Dianova,
1:2000) and a donkey-anti-goat cyanine 3-labelled Ig (Dianova,
1:200) were applied. Recombinant rNS3RMU10-3382 protein
including a cleavable Thioredoxin/His6 tag was expressed in
bacteria and purified under non-denaturing conditions following a
standard protocol [47]. The untagged purified protein was used to
produce specific rabbit polyclonal antisera at Thermo Scientific
Pierce custom antibody service. Rabbit antiserum against
rNS3RMU10-3382 (1:2000) was used in parallel to an
rNS3RMU10-3382-reactive rodent serum (1:50) for a co-localiza-
tion study by confocal laser scanning microscopy. Here, secondary
detection was performed using a cyanine 2-labelled goat-anti rabbit
Ig (Dianova, 1:200) and a cyanin 3-conjugated goat-anti-mouse Ig
(Dianova, 1:200).
In-situ hybridization
RNAScope RNA probes targeting a 978 nucleotide NS3 gene
fragment of the M. glareolus clade 1 hepacivirus detected in
specimen RMU10-3379 were custom designed by Advanced Cell
Diagnostics (Hayward, CA, USA). RMU10-3379 was selected due
to best tissue quality and high virus concentration. In-situ
hybridization was performed as described by the manufacturer.
Accession numbers
All virus sequences reported in this study were submitted to
GenBank under accession numbers KC411776-KC411814.
Results
Specimens from 8,777 individual animals from the orders
Chiroptera, Rodentia, Carnivora and Perissodactyla were included
in this study. The geographical origins of samples are summarized
in Figure 1AB. The sample contained sera and liver tissue from
4,770 rodents (Rodentia, 41 species), sera from 2,939 bats
(Chiroptera, 51 species), sera from 210 horses (Perissodactyla) and
sera from 167 dogs (Carnivora). Due to the reported respiratory
tropism of canine hepaciviruses, snout swabs were additionally
obtained from 239 dogs and 452 cats. The detailed composition of
the sample is listed in Supplementary Table 1.
Pre-screening by serology
Enough serum for serologic testing was available from 180 bats
(72 Rousettus aegyptiacus and 108 Eidolon helvum) and 95 rodents (33
Myodes glareolus, 30 Apodemus sylvaticus, 30 Rattus norvegicus, 2
Myocastor coypus). In initial tests using immunofluorescence slides
containing full recombinant HCV, 13 bats (7.2%, 9 R. aegyptiacus
and 4 E. helvum) showed reactivity patterns suggestive of antibodies
cross-reacting with HCV. Figure 2A exemplifies typical IFA
reaction patterns observed. For confirmation, recombinant HCV
western blot (WB) assays certified for diagnostic application in
humans were adapted for use with bat and rodent sera. For 95 of
the 180 bat sera, enough serum volume for WB testing was
available. This included three of the 13 IFA-positive sera. As
shown in Table 1, between seven (Core) to 28 (NS3/Helicase)
sera were clearly reactive with different WB antigens. 10 sera
(10.6%) were to be interpreted as antibody-positive upon criteria
for the interpretation of western blot results applicable in human
diagnostics. Figure 2B provides examples of typical reaction
patterns. The three IFA-positive sera were also positive in WB. For
rodents, Table 1 shows that two (Helicase and NS4) to six (NS5B)
sera reacted with individual antigens. Another 45 sera showed
borderline reactivities comparable to the intensity of the WB cut-
off control (examples of reactivities in Figure 2C). No rodent sera
fulfilled the criteria for positive interpretation applicable in human
diagnostics.
Hepacivirus detection
For the molecular analysis of bats, 2,939 sera from Gabon,
Ghana, Papua-New Guinea, Australia, Thailand, Panama and
Germany were tested for Hepacivirus RNA using several broadly
reactive and highly sensitive RT-PCR assays, as detailed in
Supplementary Table 2. Despite the apparent relatedness of
putative bat hepaciviruses with HCV suggested by the serologic
analyses, no hepacivirus RNA was detected in any of the
specimens, whereas several PCR fragments from the NS3 gene
were obtained which upon sequencing were identified as
pegiviruses related to GBV-D [48].
Tested rodent specimens originated from Thailand, Gabon,
South Africa, Germany, the Netherlands and Mexico (Supple-
mentary Table 1). HCV-related sequences from the NS3 gene
were detected in 37 out of 4,770 specimens (0.8%). Ten of these
findings were from South African four-striped grass mice
(Rhabdomys pumilio; 10 of 518 individual animals, 1.9%). For these
and all other positive specimens, a 978 nucleotide NS3 fragment
was generated using additional primer pairs (Supplementary
Table 2). The derived sequences pertained to one clade, and were
different from each other by 21.1% on nucleotide, or 3.4% on
translated amino acid level. Twenty-seven (1.8%) of 1,465
individual bank voles (Myodes glareolus) from Germany and The
Netherlands yielded HCV-related NS3 sequences. The derived
sequences fell into two separate clades. Clade 1 contained 23
sequences different from each other by up to 15.8% of nucleotides
and 2.8% of translated amino acids. Clade 2 contained four
sequences different by 1.6% nucleotides and 0.6% translated
amino acids.
A Bayesian phylogeny of the partial NS3 gene shown in
Figure 3A suggested that the M. glareolus hepacivirus clade 1 was
monophyletic with HCV and the canine/equine hepaciviruses. M.
glareolus hepacivirus clade 2 was most closely related to GBV-B
while the R. pumilio-associated clade formed a sister taxon to all
other hepaciviruses. An analysis of all replicate trees indicated that
the deep phylogenetic nodes were not resolved (Figure 3A). The
monophyly of HCV and the M. glareolus clade 1 hepaciviruses was
maintained in 68.6% of tree replicates (3,430 of 5,000). In another
28.9% of trees (1,446/5,000), the two M. glareolus hepacivirus
clades clustered together. Monophyly of all three rodent
Rodent Hepaciviruses
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hepacivirus clades and GBV-B was indicated in only 15 of 5,000
tree replicates (0.3%).
Full genome characterization
The near full genomes of five representative hepaciviruses from
all rodent clades were determined, including two viruses from R.
pumilio, two from M. glareolus clade 1 and one from M. glareolus
clade 2 (identified by red squares in Figure 3A). The polyprotein
genes were of different sizes including 2,781; 2,887; and 3,007
amino acid residues, respectively, compared to 3,008–3,033 in
HCV. All genomes shared the typical hepacivirus polyprotein
organization, encoding putative proteins in the sequence C-E1-E2-
p7-NS2-NS3-NS4A/4B-NS5A-NS5B (Figure 3B). The putative
structural C, E1, E2 and p7 proteins were predicted by signal
peptidase cleavage site analysis (Supplementary Table S3) to
be comparable in their sizes to that of known hepacivirus proteins.
Figure 1. Sampling sites, years, species and families. A. Sampling sites yielding novel hepaciviruses are indicated in red, others in yellow. B.
Placentalia (Eutheria) evolutionary lineages according to [76]. Major mammalian clades are identified at basal nodes of the Placentalia phylogeny:
Afrotheria (e.g., elephants), Xenarthra, (e.g., anteaters) and Boreoeutheria, divided into the two superorders Euarchontoglires, (e.g., primates, rodents)
and Laurasiatheria (e.g., dogs, bats). Sampled mammalian orders are shown in boldface type. Orders containing novel hepaciviruses identified in this
study are shown in red and boldface. Orders with known hepaciviruses (perissodactyla, primates, carnivora) are given in red. Numbers of extant
families and species per order adapted from [33] are indicated.
doi:10.1371/journal.ppat.1003438.g001
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All rodent viruses had considerably fewer predicted glycosylation
sites in their structural proteins, in particular their putative E2
proteins, as opposed to HCV. A detailed genome analysis is
provided in Figure 3B. The 59-terminus of the core gene of the R.
pumilio hepacivirus clade contained a putative adenosine-rich
slippery sequence at codons 10–14 (AAAAAAAACAAAAA,
Supplementary Figure 3B). In HCV, a very similar sequence
(AAAAAAAAAACAAA), located at nearly the same positions
(codons 8–12) of the core gene induces production of a protein
termed F in vitro due to ribosomal frameshift event [49].
Depending on the HCV genotype, the size of the F protein
ranges from 126 to 162 amino acid residues which vary
considerably in sequence composition [50]. The size of a putative
F protein in SAR46 would be 65 amino acid residues and no
homology to the HCV F proteins was observed.
The total amino acid diversity of all homologous genes within
the polyproteins of the three rodent hepacivirus clades was larger
than that of all HCV genotypes (Supplementary Table S4).
Similar to HCV, the most variable genomic regions in rodent
hepaciviruses were located in the Envelope E2 gene differing in up
to 84.4% of encoded amino acids between the rodent virus clades;
the NS2 gene differing in up to 79.8%; and the NS5A gene
differing by up to 84.6%.
The high degree of sequence homology of the RNA-dependent RNA
polymerase (RdRp) genes between all members of the family Flaviviridae
enabled a more comprehensive comparison of the novel viruses. In
a Bayesian phylogeny of these genes across the flavivirus family, the
rodent viruses formed a monophyletic sister-clade to HCV
(Figure 4A). Topological robustness was assessed by the fixation,
in parallel Bayesian phylogenies, of two alternative topological
hypotheses, the first involving monophyly of HCV with the canine/
equine viruses and M. glareolus clade 1, and the second assuming a
separation of HCV and the canine/equine viruses from all rodent
viruses and GBV-B. A Bayes factor test comparing the total model
likelihood traces of these analyses indicated borderline-significant
preference of the second hypothesis over the first (Log10 Bayes
factor = 2.94). Figure 4B provides a comparison of RdRp-based
amino acid distances within and between Flaviviridae genera.
In a Bayesian phylogeny of the full polyprotein, the rodent
hepaciviruses and GBV-B were monophyletic, forming a sister
Figure 2. Serological reactivity of bat and rodent sera with HCV antigens. A. Indirect immunofluorescence assay using bat serum. Typical
reactivity of a positive E. helvum serum from Ghana (GH69) diluted 1:50 in sample buffer with HuH7 cells infected with HCV strain JHF1 is shown on
the left. Arrows point at specific staining of cytoplasmatic antigen. On the right, lack of reactivity of GH69 with uninfected HuH7 cells is shown. IFA
was done as described in the methods section. Cell nuclei were stained with DAPI. Scale bar represents 100 mm. B. HCV western blot reactivity
patterns with bat sera. Representative reaction patterns of 11 bat sera with the HCV recomblot assay are shown. Sample 1, human positive control
serum. Samples 2 to 12 correspond to the following bat species: 2–7, Eidolon helvum; 8–12, Rousettus aegyptiacus. C. HCV western blot reactivity
patterns with rodent sera. Representative reaction patterns of 5 rodent sera with the HCV recomline are shown. Sample 1, human positive control
serum. Samples 2 to 6 correspond to the following rodent species: 2, Rattus norvegicus; 3, Apodemus sylvaticus; 4, Myocastor coypus; 5, Rattus
norvegicus; 6, Myodes glareolus. Blot antigens are indicated at the left of each row. Below each line in B and C, the result of a tentative evaluation is
given following the manufacturer’s criteria defined for human sera, as described below Table 1.
doi:10.1371/journal.ppat.1003438.g002
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clade to the canine/equine hepaciviruses and HCV (Figure 5).
The rodent-associated clade had very long intermediary branches
and originated close to the root of all viruses. The full genome tree
had a better phylogenetic resolution compared to the partial NS3
phylogeny, but still contained topological uncertainties in some
deep nodes leading to rodent-associated taxa (Supplementary
Figure S1).
The genome ends of representatives of all three rodent viruses
were determined, including virus RMU10-3382 belonging to M.
glareolus clade 1, NLR-AP-70 belonging to M. glareolus clade 2, and
virus SAR-46 belonging to the R. pumilio hepacivirus clade.
Figure 5 and Supplementary Figure S2A show that the 59-
genome terminus of RMU10-3382 contained structural elements
typical of both pegi- and HCV-like internal ribosomal entry sites
(IRESs). Predicted structural similarities with the HCV-like IRES
included the first stem-loop element (termed Ia and highlighted in
orange in Figure 5) and one of two sites involved in miRNA122
binding [51], while most of the remaining stem-loop elements
(termed 3, 4 and 5 and highlighted in blue in Figure 5) were more
closely related to a pegivirus-like IRES. The 59-end of AP-70 was
identical in structure to RMU10-3382 and contained only a few
nucleotide exchanges. SAR-46 contained the typical HCV-like
IRES structures including the characteristic stem-loop III
(Figure 5 and Supplementary Figure S2B). The observed
structural similarity between the first stem-loop of all rodent
viruses described here and the prototype hepaciviruses HCV and
GBV-B consisted of a hairpin with a six-nucleotide stem and four-
five nucleotide loop. The equine/canine hepaciviruses contained a
similar structural element located as their second predicted IRES
domain, instead of the most 59-position this domain occupied in all
other hepaciviruses. The RMU10-3382 and NLR-365 translation
initiation sites contained a cytosine immediately following the
putative start codon at position +4, which is suboptimal in the
original Kozak sequence context (ACCATGG) but should not
block initiation [52]. The 39-ends of RMU10-3382 and SAR-46
contained three highly ordered stem-loop elements. In RMU10-
3382, these RNA elements did not resemble any known 39-
noncoding sequence RNA structure. In SAR-46, the 39-terminal
stem-loop structure, but not the preceding structures, resembled
that of the HCV X-tail (Figure 5 and Supplementary Figure
S3). A similar 39-terminal structure could be predicted for GBV-B,
but not for the genetically related pegiviruses (Figure 5 and
Supplementary Figure S4). The 39-end of NLR-AP-70 could
not be determined. Contrary to HCV and GBV-B, no poly-uracil
stretch was observed in the rodent hepaciviruses.
Natural history of hepacivirus infection in bank voles
Strain-specific real-time RT-PCR assays were used to determine
viral RNA concentrations in tissues of 22 bank voles infected with
clade 1 and 2 hepaciviruses. Mean RNA concentrations were
highest in liver tissue (1.86108 copies/gram; range, 1.56106–
4.46109). These concentrations were significantly higher than
those in other organs or serum (ANOVA, F = 7.592, p,0.0001;
Figure 6A and Supplementary Figure S5). Figure 6B shows
M. glareolus clade 1 hepacivirus RNA stained by in-situ hybridiza-
tion (ISH) in liver tissue. Foci of viral RNA were located in the
cytoplasm of M. glareolus hepatocytes, while no staining was
observed in RT-PCR-negative M. glareolus liver specimens
(Supplementary Figure S6 shows additional ISH details).
Spleen, kidney, heart and lung tissues yielded no evidence of virus
infection by ISH. Histopathological examination of eight RNA-
positive and two RNA-negative animals revealed low-grade focal
lymphocytic invasion compatible with liver inflammation, such as
shown in Figure 6C for two exemplary RNA-positive animals.
Serological investigations in wild rodents were complicated by
the fact that the vast majority of animals from virus-positive species
were not live-trapped, therefore yielding no blood samples. Only
post mortem peritoneal lavage fluids were collected from carcasses,
but these were not qualified for serology. However, a subset of 97
live-trapped M. glareolus with appropriate blood samples were
Table 1. Western blot reactivity patterns.
Interpretation* Reactivities by individual antigens
Western Blot NS3 Helicase NS5 NS4 Core
Bat species N + ± 2 + ± 2 + ± 2 + ± 2 + ± 2 + ± 2
Eidolon helvum 89 7 18 64 22 39 28 26 36 27 9 35 45 6 22 61 5 20 64
Rousettus aegyptiacus 5 3 2 0 5 - 1 2 3 1 2 1 3 1 2 3 2 1 3
Total (percent) 94 10 (10.6) 20 (21.3) 64 (68.1) 27 39 29 28 39 28 11 36 48 7 24 64 7 21 67
Rodent species
Myodes glareolus 33 0 1 33 - - - 1 5 - 2 7 - - 2 - - - -
Apodemus sylvaticus 30 0 1 29 - 1 - - 2 - 1 7 - - 4 - - 1 -
Rattus norvegicus 30 0 0 30 - - - 1 2 - 3 8 - - 6 - - - -
Myocastor coypus 2 0 0 2 - - - - - - - - - 2 - - - - -
Total (percent) 95 0 2 (2.1) 94 (97.9) 0 1 0 2 9 0 6 22 0 2 12 0 0 1 0
*Blot analysis criteria for human diagnostics provided by the manufacturer (Microgen, Neuried, Germany): A positive band was assigned the following point values: NS3,
3; Helicase, 3; NS5-12, 2; NS4, 4; Core, 8. Only weakly positive bands (visible, but weaker than the core antigen of the weak positive HCV control) were considered
negative with the exception of the core antigen, which was then assigned 5 points. Blots were considered positive if the sum of points was equal to or greater than 10,
borderline if the sum was between 6 and 9 points, and negative if the sum was equal to or below 5 points. Eight bat sera showing strongest Western Blot reactivity were
end-point diluted to evaluate specificity of the reaction. Bands remained visible up to a dilution of 1:400. Some analyses were done using a follow-up version of the
Microgen assay (recomline) with two separate core antigens and different interpretation criteria. Blots were then considered borderline if any two antigens showed
higher intensity than a cut-off control, the helicase alone, the helicase and any NS antigen or any core epitope. Blots were considered positive in this assay version if
both core antigens were positive, one core plus any other antigen or if three antigens showed higher intensities than the cut-off control. Reactivity of the secondary
goat anti-mouse and tertiary donkey anti-goat antibodies used for rodent testing were controlled by using mouse anti-core and anti-NS3 monoclonal antibodies for
primary reaction with blot antigens.
doi:10.1371/journal.ppat.1003438.t001
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available. These were analyzed for antibodies against the Myodes
hepacivirus clades 1 and 2 in an IFA using cells expressing the NS3
antigens of these viruses. Antibodies against the Myodes hepacivirus
clade 1 NS3 antigen were found in eight animals (8.3%) at a
median end-point titer of 1:200 (range, 1:100–1:1600). Antibodies
against the Myodes hepacivirus clade 2 NS3 antigen were detected
in 12 animals (12.4%) at a median end-point titer of 1:600 (range,
1:100–1:12800). The difference in antibody detection rates against
clades 1 and 2 was not statistically significant (X2 = 0.5, p = 0.5).
Myodes hepacivirus clade 1 antigen specificity was proven by
counterstaining with a high-titered rabbit serum raised against the
same recombinant NS3 antigen down to dilutions of .1:20,000.
Myodes hepacivirus clade 2 antigen did not cross-react with this
rabbit control serum even at high concentrations of 1:100,
compatible with low NS3 amino acid sequence identity between
the NS3 proteins of the two Myodes hepacivirus clades (42.4%,
Supplementary Table S4). Neither hepacivirus clade 1, nor
clade 2 antibody-positive sera cross-reacted with HCV by
immunofluorescence and by immunoblot, indicating specific
immune reactions against the viruses studied (exemplary results
in Figure 6D). This was compatible with low NS3 amino acid
sequence identities between both Myodes hepacivirus clades and
HCV, ranging from 37.9–42.2% (Supplementary Table S4).
Only one of the eight sera positive against M. glareolus clade 1
hepaciviruses also contained antibodies against M. glareolus clade 2
hepaciviruses (titers against clade 1 and clade 2 hepaciviruses were
1:200 and 1:3200, respectively).
Additional highly sensitive real-time RT-PCR assays were
designed specifically for the M. glareolus clade 1 and 2 hepaciviruses
and used to analyze the association of viral RNA and antibody
status in the 97 M. glareolus sera. No hepacivirus RNA was detected
in any of the IFA-positive sera, neither with the broadly reactive
screening assays, nor with the additional real-time RT-PCR assay.
Therefore, another 239 RNA eluates still containing sufficient
volumes to permit screening for M. glareolus clade 1 and 2
hepaciviruses were re-tested with the strain-specific real time RT-
PCR assays. Another 57 specimens positive for clade 1 hepaci-
viruses (23.9%), but no additional clade 2 hepaciviruses were
detected. Sera from these PCR-positive animals were obtained and
tested for antibodies. Three of the 57 clade 1 RNA-positive sera
contained antibodies against clade 1 hepaciviruses (5.3%).
Because of previous reports of canine/equine hepaciviruses, all
RT-PCR assays used in this study were also applied on specimens
from horses, cats and dogs. No HCV-related sequences were
found in any of the 858 canine or feline specimens. In seven of 210
horse sera (3.3%), sequences closely related to those equine
hepaciviruses described previously from the US and New Zealand
[24] were detected (9.5–15.0% exchanges in the 978 nucleotide
NS3 gene fragment). Most of those nucleotide differences
represented synonymous mutations, resulting in low amino acid
distances of 0–1.2%. The novel hepaciviruses from German horses
clustered phylogenetically with the previously described equine
viruses (Figure 3A).
Discussion
Here we found molecular evidence for viruses related to HCV
in rodents. Rodent hepaciviruses were detected in four-striped
grass mice from South Africa, as well as in bank voles from Central
Europe. The latter have already been successfully bred under
laboratory conditions, indicating an approach to establish
surrogate models for hepacivirus infection [53,54,55,56].
All discovered viruses originated from deep nodes close to the
bifurcations separating genera within the flavivirus tree. In
phylogenies on whole genome and individual gene alignments,
the novel viruses clustered in a monophyletic clade with previously
known hepaciviruses and GBV-B. The clade is highly diversified
with NS5b amino acid sequence distances between taxa ranging
up to 66.1%, exceeding that in the well-studied genus Flavivirus
(55.8%). Maximal distances within the genera Pegivirus (52.9%) and
Pestivirus (42.0%) are even lower, suggesting a particularly high
diversity to exist in a tentative genus defined by the novel clade.
Whereas this indicates that some or all of the novel rodent viruses
together with GBV-B might alternatively form an independent
genus, recent descriptions of novel pegi- and pestiviruses in bats
and swine suggest the diversity also within these genera to be
understudied [48,57,58].
Including the novel rodent viruses congeneric with HCV and
canine/equine viruses, the minimal distance between the genera
Hepacivirus and Pegivirus would be 73.5%. While this is lower than
the 85–88% between other pairs of genera, it is consistent with a
separation threshold of 72.2% between all members of the genus
Flavivirus and Tamana bat virus, for which a separate genus has
been proposed [59]. This also corresponds to inter-generic
distances within other well-studied families of plus-strand RNA
viruses such as the Picornaviridae, whose twelve genera are mostly
separated by 70–80% in the RdRp-encoding 3D gene [60]. The
Figure 3. Genomic characterization of the novel rodent hepaciviruses. A. Partial NS3 gene phylogeny. The analysis comprised a 978
nucleotide fragment of the HCV NS3 gene corresponding to positions 3,912–4,889 in HCV 1a H77 (GenBank, NC_004102). GenBank accession
numbers of reference hepaciviruses are indicated to the right of taxon names. Tree topology was inferred using BEAST with a GTR nucleotide
substitution model as described in the methods section. Rodent hepaciviruses from this study are shown in red and boldface, equine hepaciviruses
from this study are shown in blue and boldface. Red squares indicate those viruses whose near full-length genomes were generated. Statistical
support of grouping is shown as posterior probabilities at deep nodes. Scale bar corresponds to genetic distance. To the right, 5,000 tree replicates of
the same analysis are rendered using Densitree (initial 5,000 trees discarded as burn-in). Green line color indicates low probability of all trees, line
thickness corresponds to concordant topologies across tree replicates. B. Genome organization of the novel rodent hepaciviruses. Genes were
annotated as described in the methods section. Black arrows on the top indicate predicted signal peptidase cleavage sites. Red arrows below indicate
N-, blue arrows O-glycosylation sites. Putative gene starts and ends are numbered below polyprotein plots. HCV 1a strain H77 is depicted on top as a
reference. RMU10-3382 (KC411777) also represents the highly similar virus NLR-365 (KC411796) in M. glareolus hepacivirus clade 1. SAR-46 (KC411807)
also represents SAR-3 (KC411806), both from the R. pumilio hepacivirus clade. GenBank accession number of NLR-AP70 representing M. glareolus
hepacivirus clade 2 is KC411784. The structural genome region included Core (C), Envelope 1 and 2 (E1 and E2) and p7 genes. The boxes in the HCV
and SAR-46 Core gene indicate a putative F protein open reading frame. The putative Core gene at the N9-terminus of the rodent hepacivirus
polyproteins included a high number of strongly basic lysine and arginine residues (M. glareolus clade 1, 29 of 163 residues (17.8%); M. glareolus clade
2, 23 of 149 (15.4%); R. pumilio clade, 28 of 172 (16.3%); compared to 31 of 191 (16.2%) in HCV-1a and 11 of the N9-terminal 200 residues (5.5%) in the
pegivirus GBV-C1 not encoding a Core protein. Non-structural genes included an NS3 protease/helicase gene, the phosphoprotein NS5a and the NS5b
gene encoding the RNA-dependent RNA polymerase. Within the NS4 gene, only the NS4b portion could be clearly identified for all viruses. An NS4a
homologue could only be detected in virus SAR-46. IRES types and structural elements in the 39-genome ends are depicted adjacent to the
polyprotein plots for viruses NLR-3382 and SAR-46. Of NLR-AP70, only the 59-end could be partially determined. This sequence was almost identical to
RMU10-3382/NLR-365. The 39-terminus of NLR-AP70 could not be determined.
doi:10.1371/journal.ppat.1003438.g003
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Figure 4. Comparison of the novel rodent hepaciviruses with other Flaviviridae. A. Bayesian phylogeny of the Flaviviridae NS5B gene. The
analysis was done in MrBayes and included representatives of all Flaviviridae genera and those five novel rodent viruses whose full polyprotein could
be determined. The WAG amino acid substitution model was used. Statistical support of grouping from Bayesian posterior probabilities and 1,000
parallel Maximum Likelihood bootstrap replicates is indicated at deep node points. Scale bar corresponds to genetic distance. A tombusvirus
(Lisianthus necrosis virus, GenBank accession number NC_007983) was chosen as an outgroup. B. Amino acid distance of the complete NS5B gene
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within Flaviviridae clades. Maximum amino acid sequence distance was calculated with MEGA5 using the pairwise deletion option and all Flaviviridae
members contained in panel A. The dotted line indicates 70% distance for clarity of graphical presentation only.
doi:10.1371/journal.ppat.1003438.g004
Figure 5. Complete polyprotein gene phylogeny and comparison of the genome termini between the novel rodent and prototype
hepaciviruses. For the Bayesian phylogeny shown to the left, the WAG amino acid substitution model was used in MrBayes as indicated in the
methods section. Statistical support of grouping from Bayesian posterior probabilities is indicated at node points. Scale bar corresponds to genetic
distance. The Pestivirus BVDV (NC_001461) was chosen as an outgroup and truncated for graphical reasons. Branches leading to the novel
hepaciviruses from this study are in orange. GenBank accession numbers of analyzed hepaciviruses correspond to those indicated in Figure 3A. The
59- and 39-genome termini were re-drawn from published foldings for equine hepaciviruses [24], HCV [63,77] and GBV-B [78] and de novo for this
study for the 59- and 39-ends of GBV-C1 and the 39-end of GBV-B (see Supplementary Figure 4). Despite earlier attempts to fold the 39-ncr of GBV-B
[21] only the 39-terminal stem-loop structure of GBV-B could be reliably folded due to the single sequence available. The folding of the 39-end of
RMU10-3382 remained tentative for the same reason. No sequence information was available for the 39-ends of the canine/equine hepacivirus clade
and M. glareolus hepacivirus clade 2 (indicated as ‘‘n.a.’’). Typical pegivirus domains are highlighted in blue and ordered by arabian numbers. Typical
hepacivirus domains are highlighted in orange and numbered by roman numbers.
doi:10.1371/journal.ppat.1003438.g005
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Figure 6. Presentation of hepacivirus infection in bank voles. A. Hepacivirus RNA concentrations in Myodes glareolus. Bars represent means
and standard deviation of hepacivirus clade 1- and 2-positive organs and serum. The number of biological replicates is indicated below bars. B. In situ
hybridization of rodent hepacivirus clade 1 RNA in M. glareolus. Viral RNA was stained in liver tissue of M .glareolus specimen RMU10-3379 (viral RNA
concentration, 9.46108 copies per gram, GenBank accession no. KC411778). The RNA-negative specimen RMU10-3187 from the same species was
processed identically and is shown below as a control. Positive staining is visible as distinct red granules in the cytoplasm of hepatocytes.
Magnification was 1006, the inserts shows details of single hepatocytes in 106 higher magnification. Scale bars are shown to the lower right. C.
Histopathology of M. glareolus liver specimens. Liver sections were stained by Hematoxylin and Eosin (H&E) and Epson van Giesson (EvG) stains. In
H&E stains, black arrows point to inflammatory lymphocytic infiltrate. In EvG stains, black arrows highlight potential signs of fibrosis. Specimen 3180
shows intermediate portal inflammatory lymphocytic activity with potential low-grade fibrosis in a case with high hepacivirus RNA concentrations
(1.56108 copies/gram). Specimen 1602 shows low-grade portal inflammatory activity and low-grade fibrosis in a case with high hepacivirus RNA
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genomic organization of the novel viruses provides additional
criteria for tentative classification. Like all hepaciviruses and in
contrast to all members of the genus Pegivirus, the novel viruses
have a discernible core gene [61]. In contrast to the genus Pestivirus
[62], their genomes contained no putative Npro and Erns genes in
any reading frame. Finally, in contrast to the genus Flavivirus [63],
all rodent viruses showed IRES secondary structures in their 59-
genome termini. Some of the novel rodent IRES structures
appeared to contain both elements related to type 3 IRES known
from hepaci- and pestiviruses and type 4 IRES known from
pegiviruses. Additionally, both M. glareolus rodent hepacivirus
polyprotein clades were preceded by predominantly pegivirus-
related IRES structures, while the R. pumilio hepacivirus clade was
preceded by a predominantly hepacivirus-related IRES. This may
be compatible with ancient recombination events between
Flaviviridae genera, a phenomenon known in the family Picornavir-
idae [64,65].
The genetic elements potentially homologous to HCV detected
in rodent viruses also included microRNA-122 binding sites in the
59-ncr, an X-tail-like element in the 39-terminus and a putative F
gene in an alternative open reading frame (ORF) of the R. pumilio–
associated virus. The F protein appears to be unessential for HCV
replication, but the evolutionary conservation of its ORF suggests
that it may play a critical regulatory role in virus propagation and
survival [50]. In this regard, the F protein may be considered a
counter-defensive security protein that evolved to overcome
mechanisms of host resistance [66]. The absence of paramount
features typical of other genera and the presence of hepacivirus-
like features suggest a tentative classification of the novel rodent
viruses within the genus Hepacivirus, rather than a novel genus.
Within the genus, phylogeny suggests early divergence of
ancestral rodent viruses from a lineage leading up to HCV and
canine/equine hepaciviruses. Weakness of resolution in deep
bifurcations of the NS3 gene phylogeny and lack of any highly
significant preference for deep topological hypotheses in the NS5B
gene phylogeny underline the ancestral origin of these viruses.
Within the current dataset we can consider them equidistant from
HCV and the canine/equine hepaciviruses, suggesting existence of
independent taxonomic entities. HCV is one viral species whose
genotypes are separated by more than 30% genomic nucleotide
distance [67], which corresponds to about 22–31% AA distance.
Different species within the related sister genus Pegivirus, such as
GBV-C and GBV-A, are separated from each other by about 45%
AA distance [68]. Within the Genus Flavivirus, well-defined species
such as dengue virus 1, West Nile virus, yellow fever virus and tick-
borne encephalitis virus are separated from each other by 48–60%
AA distance. Comparing these values we could putatively assume
that both Myodes-associated clades distant from each other by 70%
AA sequence, as well as the Rhabdomys-associated clade separated
from both of the aforementioned by 66–69% AA sequence, might
form three distinct species. The canine/equine hepacivirus clade
separated from HCV by 52–53% AA sequence would then also
form a separate species. Furthermore, all rodent hepacivirus clades
and specifically M. glareolus hepacivirus clade 2 were slightly more
related to GBV-B than to HCV. GBV-B causes hepatitis in
experimentally infected New World primates but not in humans
and chimpanzees [61]. The true host of this virus is unknown, but
our findings suggest that GBV-B might originate from rodents.
Nevertheless, the genetic distance of GBV-B even to its closest
relative, the Myodes hepacivirus clade 2 (63% AA sequence),
suggests GBV-B to remain a solitary representative of a separate
species of hepaciviruses.
In the canine/equine clade (also termed non-primate hepaci-
viruses or NPHV [23]), it is striking that almost identical viruses
have been found in horses and dogs. Additionally, horses but not
dogs had antibodies against those viruses [24]. In the present study
we augmented the number of studied dogs and horses consider-
ably, and investigated cats in addition as these are related in the
order of carnivores and have shared domestic habitats with dogs
over a long history. The complete absence of viruses in cats and
dogs, and the confirmation of highly similar viruses in other
geographic regions, here and in another recent study [69], suggest
an actual equine association of the canine/equine clade. Whether
acquisition of viruses might have occurred during the domestica-
tion of horses, or whether a more generic viral association with the
equine stem lineage may exist, could be clarified by testing non-
domestic equids such as wild asses or zebras. However, the overall
phylogenetic position and monophyly of equine viruses suggest no
role as ancestral hepacivirus hosts for horses. While the rodent
hepaciviruses greatly extended the genetic diversity of the genus
Hepacivirus, their role in the evolution of HCV precursors, if any,
remains to be determined.
Our serological evidence for hepaciviruses in bats is noteworthy
even in absence of direct virus findings. Viruses from all Flaviviridae
genera including Pegivirus, Pestivirus and Flavivirus have already been
found in bats [48,70,71]. We could not exclude that the antibodies
in bat sera reacting with HCV antigens were directed against
viruses from other Flaviviridae genera, rather than bat hepaci-
viruses. However, there was no cross-reactivity between the NS3
proteins of the more closely related canine/equine hepaciviruses
and HCV [24]. Similarly, the two bank vole hepacivirus clades
from our study showed no serologic cross-reactivity. These data
can therefore serve as very initial suggestions for the existence of
bat hepaciviruses only. It should be noted that the degree of
genomic similarity necessary for serologic cross-reactivity should
have permitted RNA detection by the broadly reactive PCR assays
used in this study. Whether bat hepaciviruses indeed exist will
therefore require further evidence. A first step to this direction may
be an analysis of an expanded bat sample by using the methods
presented here.
Additional to phylogeny and genomic properties, the novel
viruses resemble HCV in important traits of the natural history of
infection. The detection of non-identical virus sequences in natural
groups of animals, in combination with specific antiviral antibod-
ies, proves continuous transmission of virus among animals.
Induction of controlled infections in housed animals should thus
be feasible. We found clear in-vivo evidence for hepatic tropism by
demonstrating histopathological signs of liver inflammation,
concentrations (3.46108 copies/gram). Specimen 3187 shows no significantly increased inflammatory activity and no signs of fibrosis in a case with
no detectable hepacivirus RNA. Due to highest tissue quality, a terminal hepatic venule instead of a portal triad is shown. D. Recognition of rodent
hepacivirus clade 1 antigens by M. glareolus serum. VeroFM cells expressing complete NS3 from M. glareolus hepacivirus RMU10-3382 (GenBank,
KC411777) were incubated with 1:2000-diluted rabbit-anti-NS3 3382 antiserum (control) or 1:50-diluted rodent serum (picture shows exemplary
results for animal NLR 3/C12), followed by goat-anti-rabbit-Cy2 (green) and goat-anti-mouse-Cy3 (red) secondary immunoglobulins. For co-
localization analysis of fluorescence signals, the 6th of 12 1-mM Z-stags is shown for every channel. Cross-reactivity with HCV antigens was analyzed
by incubation of HuH7 cells, transfected with HCV replicon JFH1, with a rabbit-anti-human-HCV-NS3-49 serum, diluted 1:400 (control) or rodent
serum NLR 3/C12 diluted 1:50, followed by goat-anti-rabbit-Cy2 (green) and goat-anti-mouse-Cy3 (red) secondary antibodies. Counterstaining was
performed using DAPI. Bar, 25 mm.
doi:10.1371/journal.ppat.1003438.g006
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excessive viral RNA concentrations in the liver, as well as in-situ
hybridizations demonstrating intracellular genome replication in
liver cells of bank voles. A somewhat lower degree of hepatic
inflammation compared to that in some HCV-infected humans
might be due to the shorter life span of bank voles rarely exceeding
1–2 years in the wild, or due to a higher capacity of tissue
regeneration [72,73]. Interestingly, our serological investigations
suggested bank voles might be able to clear hepacivirus infections,
as antibodies did not co-occur with RNA in most, but not all
animals [1]. Bank voles may therefore be more capable of clearing
hepacivirus infection than humans. This would be compatible with
infection patterns also observed in other Flaviviridae members,
exemplified by the flavivirus West Nile virus in rhesus macaques,
the pestivirus BVDV1 in cattle and the hepacivirus GBV-B in
experimentally infected tamarins [61,74,75]. However, it would
differ from equine hepaciviruses, in which RNA and antibodies co-
occurred [24]. Controlled infection experiments in bank voles
might yield relevant scenarios for the study of HCV persistence.
Bank voles can be kept in the laboratory with comparatively little
effort and have been used for virus infection studies, e.g., with
herpesviruses, bornaviruses, hantaviruses, and flaviviruses
[53,54,55,56]. Efforts to establish bank vole infection models
may benefit from the discovery of two highly divergent clades in
this species. Knowledge of three full genomes in total should
enable efficient rescue of virus from cDNA. Notably, the
Rhabdomys-associated virus clade has a host in even closer
relationship (on subfamily level) to Mus musculus commonly kept
in laboratories, for which powerful technologies such as gene
knock out and in-vivo imaging exist. Also for this virus clade, two
different full genomes have been determined. In the present study
focusing on viral ecology, however, we have not conducted
infection or virus rescue trials in cell cultures or animals. Due to
the strict liver tropism those viruses can be expected to be as
difficult to cultivate as HCV, and we currently lack any
possibilities to generate primary Myodes hepatocytes. The housing
of those animals is in preparation, as are attempts to rescue fully
sequenced viruses by reverse genetics. Additionally, our finding of
presence of hepaciviruses in the Murinae subfamily have triggered
more targeted ecological investigations to potentially identify
viruses from hosts in even closer relationship to Mus musculus. The
availability of rodent surrogate models of HCV infection may
obviate one of the most critical obstacles to HCV vaccine
development by obviating the need for primate experiments in
early stages of experimentation [12,34].
Supporting Information
Figure S1 BEAST polyprotein phylogeny including the
novel rodent hepaciviruses. The complete polyprotein
sequence of all hepaciviruses was analyzed in BEAST [37] using
the FLU amino acid substitution matrix and a strict clock over
10,000,000 trees sampled every 1,000 generations. After exclusion
of 2,500 trees as burn-in, all trees are depicted using Densitree
[39]. Blue color corresponds to most probable topologies, red to
second-best, green to third-best and dark green to remaining
topologies. 6,950 of 7,500 trees replicates (92.7%) yielded a
monophyletic origin of the rodent hepacivirus/GBV-B clade. M.
glareolus hepacivirus clade 1 clustered with HCV in 24 of 7,500
trees (0.3%). Hepaciviruses included were SAR46 (GenBank,
KC411807) and SAR3 (KC411806) from Rhabdomys pumilio,
RMU10-3382 (KC411777), NLR-365 (KC411796) and NLR-
AP70 (KC411784) from Myodes glareolus, HCV-1a (NC_004102),
HCV-2a (AB047639), HCV3a (X76918), HCV-4a (Y11604),
HCV-5a (Y13184), HCV-6a (AY859526) and HCV-7
(EF108306), Canine/Equine hepaciviruses CHCV (JF744991),
NPHV-NZP-1 (JQ434001), NPHV-A6-006 (JQ434003), NPHV-
G5-077 (JQ434006), NPHV-B10-022 (JQ434004), NPHV-H10-
094 (JQ434007), NPHV-G1-073 (JQ434002), NPHV-H3-011
(JQ434008), NPHV-F8-068 (JQ434005) and GBV-B
(NC_001655).
(TIF)
Figure S2 59-non-coding genome region (59-ncr) of
European and African rodent hepaciviruses. A. 59-end of
RMU10-3382 (GenBank, KC411777). This structure was mostly
related to the Pegivirus type 4 IRES. Nucleotides conserved with
other pegiviruses are marked in red, paired compensatory
substitutions in NLR-365 (KC411796) and the partially available
NLR-AP70 5-UTR (KC411784) that support the structure are in
green. The Ia loop is very similar in length and shape to HCV and
GBV-B. The start codon is boxed in red, additional non-functional
start codons between the poly-pyrimidine stretch typical for
pegiviruses and the true start codon are boxed in blue. The
binding site for microRNA-122 is underlined. B. 59-end of SAR-46
(KC411807). This structure was mostly related to a Hepacivirus type
3 IRES. Nucleotides conserved with HCV are marked in red. The
slippery site is underlined. The start codon is boxed. Stem-loop
structures in both foldings are numbered according to Pegi- and
Hepacivirus reference strains.
(TIF)
Figure S3 39-non-coding genome region (39-ncr) of
European and African rodent hepaciviruses. A. RMU10-
3382 (GenBank, KC411777) 39-end secondary structure. B. SAR-
46 (KC411807) 39-end secondary structure. For comparison, stem-
loop (SL) SL3 of HCV1a strain H77 (NC_004102) is depicted to
the right and structural similarities are highlighted in grey.
PK = Pseudoknot.
(TIF)
Figure S4 59- and 39-non-coding genome region (39-ncr)
of GBV-C1 and 39-ncr of GBV-B. A. 59-end secondary
structure of GBV-C1/HPgV, GenBank accession no. U36380.
Nucleotides conserved with other pegiviruses are marked in red,
paired compensatory substitutions that support the structure are in
green. Stem-loop structures are numbered by order of appearance.
B. 39-end secondary structure of GBV-C1/HPgV, GenBank
accession no. U36380. C. Secondary structure of the third
HCV-like domain of GBV-B, GenBank accession no. AF179612.
Due to the single available sequence, the remaining 39-ncr could
not be reliably folded despite repeated attempts. The nucleotide
sequence immediately following the polyprotein stop codon and
directly before the stem-loop structure towards the 39-end of GBV-
B is shown.
(TIF)
Figure S5 Hepacivirus RNA concentrations in individu-
al solid organ specimens and blood. A. Hepacivirus-positive
Myodes glareolus sampled 2008–2010 in The Netherlands and
Germany. Virus concentrations are given in Log10 RNA copies
per gram of tissue scaled on the y-axis for each rodent organ tested
(x-axis). Horizontal bars represent mean virus concentrations per
organ category. The number of available specimens per organ
category is indicated below. Colors represent viruses from
individual rodents as identified in the legend. B. Viral load in
Log10 RNA copies per mL of blood in the same 21 animals. For
one animal, no blood was available.
(TIF)
Figure S6 In-situ hybridisation of M. glareolus hepaci-
virus clade 1 RNA in liver tissue. A. RNA-negative M.
Rodent Hepaciviruses
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glareolus specimen RMU10-3187 and B. RNA-positive M.
glareolus specimen RMU10-3379 (viral RNA concentration,
9.46108 copies per gram, GenBank accession no. KC411778)
were stained at identical conditions. Power of magnification is
indicated on the left. Scale bars are depicted to the lower right
corner of every panel.
(TIF)
Table S1 Sample characteristics. aGAB = Gabon, GER = -
Germany, NAM = Namibia, NEL = The Netherlands, RSA = R-
epublic of South Africa, THA = Thailand, MEX = Mexico.
(DOC)
Table S2 Oligonucleotides used for Hepacivirus RT-
PCR screening, genome sequencing and virus quantifi-
cation. aID = identity. bnumbered after CHV polyprotein
(GenBank# JF744991); cnumbered after HCV genotype 1a
polyprotein (GenBank# NC_004102);dnumbered after CHV
genome (GenBank# JF744991) eR = G/A, Y = C/T, S = G/C,
W = A/T, M = A/C, K = G/T, H = A/C/T, B = C/G/T, I = ino-
sine, FAM = 6-Carboxy-Fluorescein, JOE = 2,7-Dimethoxy-4,5-
dichloro-6-carboxyfluorescein, VIC = proprietary dye (Life Tech-
nologies, Darmstadt, Germany), BHQ = Black hole quencher,
MGBNFQ = Minor groove binder Non fluorescent quencher; f+t/
+c = Locked nucleic acids (LNA) First round RT-PCR used the
SuperScript III (SSIII) one-step RT-PCR kit (Invitrogen, Karls-
ruhe, Germany) with 5 mL of RNA, 400 nM each of 1st-round
primers or an equimolar mix of primers, 1 mg bovine serum
albumin, 0.2 mM of each dNTP and 2.4 mM of MgSO4. Second
round 50 mL Platinum Taq (Invitrogen) reactions used 1 mL of 1st-
round PCR product, 2.5 mM MgCl2 and 400 nM each of 2nd-
round primers. First round RT-PCR reactions were used a
touchdown protocol with reverse transcription at 48u for
30 minutes, denaturation at 95u for 3 minutes, followed by PCR
10 cycles of 15 sec at 94uC, 20 sec at 60uC with a decrease of 1uC
per cycle, and extension at 72uC for 45 seconds, followed by
another 40 cycles at 50uC annealing temperature. Second round
reactions used the same cycling protocol without the RT step.
RNA quantification was performed in 25 mL reaction volumes
using the SSIII One-Step RT-PCR system (Invitrogen) as
described above with 300 nmol/L of respective forward and
reverse primers and 200 nmol/L of respective probes. Amplifica-
tion involved 15 min at 55uC; 3 min at 95uC; 45 cycles of 15 sec
at 94uC, and 25 sec at 58uC. Fluorescence was measured at the
58uC annealing/extension step. Published assays from which
oligonucleotide primers were used in this study included
[35,79,80,81,82].
(DOC)
Table S3 Putative cleavage sites for cellular signal
peptidases within the N-terminal half of hepacivirus
polyproteins. NN: neural networks; HMM: hidden Markov
models (the values represent probabilities for putative SP cleavage
sites). Only SP cleavage sites predicted by both NN and HMM
were considered. All scores were re-calculated upon putting a
suggested cleavage site at amino acid position 20 of a query
polypeptide. *Y-scores were zero for these sites, however they were
supported by uncorrected S-scores (not shown). Hepaciviruses
included were SAR46 (KC411807) and SAR3 (KC411806) from
Rhabdomys pumilio, RMU10-3382 (KC411777), NLR-365
(KC411796) and NLR-AP70 (KC411784) from Myodes glareolus,
HCV-1a (NC_004102) and GBV-B (NC_001655).
(DOC)
Table S4 Minimum amino acid identity of the novel
rodent to prototype hepaciviruses. [1] Rhabdomys pumilio
clade 1 hepacivirus: SAR46 (KC411807); SAR3 (KC411806) [2]
Myodes glareolus clade 1 hepacivirus: RMU10-3382 (KC411777);
NLR-365, KC411796 [3] Myodes glareolus clade 2 hepacivirus:
NLR-AP70 (KC411784) HCV: HCV-1a (NC_004102), HCV-2a
(AB047639), HCV3a (X76918), HCV-4a (Y11604), HCV-5a
(Y13184), HCV-6a (AY859526) and HCV-7 (EF108306); Ca-
nine/Equine hepaciviruses CHV (JF744991), NPHV-NZP-1
(JQ434001), NPHV-A6-006 (JQ434003), NPHV-G5-077
(JQ434006), NPHV-B10-022 (JQ434004), NPHV-H10-094
(JQ434007), NPHV-G1-073 (JQ434002), NPHV-H3-011
(JQ434008), NPHV-F8-068 (JQ434005); GBV-B (NC_001655)
In italics: Highest identity of any hepacivirus with HCV in matrix
(canine/equine clade in all genes). Underlined: Highest identity of
any hepacivirus with GBV-B in matrix (a rodent clade in all
genes). In bold type: Smallest identity value in matrix.
(DOC)
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